Transitional Cell Carcinoma (Urothelial Cell Carcinoma) – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Transitional Cell Carcinoma (Urothelial Cell Carcinoma) – Drugs In Development, 2023’, provides an overview of the Transitional Cell Carcinoma (Urothelial Cell Carcinoma) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
- The report reviews pipeline therapeutics for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Transitional Cell Carcinoma (Urothelial Cell Carcinoma) therapeutics and enlists all their major and minor projects
- The report assesses Transitional Cell Carcinoma (Urothelial Cell Carcinoma) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Transitional Cell Carcinoma (Urothelial Cell Carcinoma) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
3D Medicines IncAbbisko Therapeutics Co Ltd
AbbVie Inc
Acrotech Biopharma LLC
Adaptimmune Therapeutics Plc
Adcentrx Therapeutics Inc
AIM ImmunoTech Inc
Akamis Bio Ltd
Akeso Inc
Alligator Bioscience AB
Alphamab Oncology
Amgen Inc
Anhui Anke Biotechnology (Group) Co Ltd
Anwita Biosciences Inc
Aravive Inc
Astellas Pharma Inc
AstraZeneca Plc
Basilea Pharmaceutica Ltd
Bayer AG
BeiGene Ltd
Bicycle Therapeutics Plc
Bio-Path Holdings Inc
BioNTech SE
Biotheus Inc
Bioviz Technologies Pvt Ltd
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Catalym GmbH
Centrymed Pharmaceutical Inc
CicloMed LLC
Clinigen Ltd
CSPC Pharmaceutical Group Ltd
Daiichi Sankyo Co Ltd
Dyadic International Inc
Eikon Therapeutics Inc
Eisai Co Ltd
Eli Lilly and Co
Ella Therapeutics Ltd
Ellipses Pharma Ltd
Evopoint Bioscience Co Ltd
Exelixis Inc
F. Hoffmann-La Roche Ltd
Genentech USA Inc
GenFleet Therapeutics (Shanghai) Inc
Genome & Co
Gritstone Bio Inc
GSK plc
Guangzhou BeBetter Medicine Technology Co Ltd
Guangzhou Yinming Biomedical Technology Co Ltd
Harbour BioMed (Guangzhou) Co Ltd
HCW Biologics Inc
Heilongjiang ZBD Pharmaceutical Co Ltd
Hengrui Yuanzheng Biotechnology Co Ltd
Hibercell Inc
HitGen Inc
Icahn School of Medicine at Mount Sinai
Immunocore Holdings Plc
Immunorock Co Ltd
Incyte Corp
Inhibrx Inc
IO Biotech Inc
iOmx Therapeutics AG
Ipsen SA
Istari Oncology Inc
IVY Pharma Inc
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Kinnate Biopharma Inc
KLUS Pharma Inc
Lee's Pharmaceutical Holdings Ltd
Lindis Biotech GmbH
Lipac Oncology LLC
Luye Pharma Group Ltd
Mabwell Shanghai Bioscience Co Ltd
Mayo Clinic
Merck & Co Inc
Millennium Pharmaceuticals Inc
Minghui Pharmaceutical (Shanghai) Co Ltd
Moderna Inc
MorphoSys AG
Mural Oncology Inc
Nanology LLC
NextPoint Therapeutics Inc
OncoQuest Inc
Orion Corp
Otsuka Pharmaceutical Co Ltd
Pfizer Inc
Pharma Mar SA
Prestige BioPharma Ltd
PRISM Pharma Co.
Ltd.
Promontory Therapeutics Inc
Pyxis Oncology Inc
RAPT Therapeutics Inc
RemeGen Co Ltd
Replimune Ltd
Sanofi
Scholar Rock Inc
Shandong Boan Biotechnology Co Ltd
Shandong Buchang Pharmaceutical Co Ltd
Shandong New Time Pharmaceutical Co Ltd
Shandong Taize Huikang Biomedical Co Ltd
Shanghai Celgen Bio-Pharmaceutical Co Ltd
Shanghai De Novo Pharmatech Co Ltd
Shanghai Fosun Pharmaceutical (Group) Co Ltd
Shanghai Henlius Biotech Inc
Shanghai Junshi Biosciences Co Ltd
Shanghai Lingda Biopharmaceutical Co Ltd
Shanghai Pharmaceuticals Holding Co Ltd
Shanghai Yingli Pharmaceutical Co Ltd
Shionogi & Co Ltd
Simcere Pharmaceutical Group Ltd
Simcha Therapeutics Inc
Sinovant Sciences HK Ltd
Sunho (China) Biopharmaceutical Co Ltd
Sustained Therapeutics Inc
SynOx Therapeutics Ltd
Systimmune Inc
UCB SA
Vaxiion Therapeutics Inc
Vaximm AG
WindMIL Therapeutics Inc
Xencor Inc
Zhejiang Teruisi Pharmaceutical Co Ltd